DolPHIN-1 is an RCT of dolutegravir versus efavirenz in women initiating treatment in the third trimester of pregnancy. These documents outline our data sharing policies and study outcome data presented at IAS 2018
Background Women with HIV and prior exposure to combination antiretroviral therapy (cART) solely fo...
Summary: Background: Global rollout of dolutegravir-based antiretroviral therapy (ART) has been ham...
Introduction: Evidence on health-related quality of life (HRQoL) outcomes is limited for new antiret...
Background: ART initiation in the 3rd trimester of pregnancy is associated with failure to achieve v...
BACKGROUND: Late initiation of HIV antiretroviral therapy (ART) in pregnancy is associated with not ...
BackgroundLate initiation of antiretrovirals in pregnancy is associated with increased risk of perin...
Background Late initiation of HIV antiretroviral therapy (ART) in pregnancy is associated with not a...
BackgroundThe global transition to use of dolutegravir (DTG) in WHO-preferred regimens for HIV treat...
Late initiation of antiretrovirals in pregnancy is associated with increased risk of perinatal trans...
Background: Effective antiretroviral therapy during pregnancy minimizes the risk of vertical HIV tra...
BackgroundRapid reduction in human immunodeficiency virus (HIV) load is paramount to prevent peripar...
Background: Pregnancy and polymorphisms in drug disposition genes alter the clearance of key antiret...
Item does not contain fulltextInformation on the extent of drug exposure to mothers and infants duri...
This case highlights the current complexities of managing women in the early stages of pregnancy pre...
Information on the extent of drug exposure to mothers and infants during pregnancy and lactation nor...
Background Women with HIV and prior exposure to combination antiretroviral therapy (cART) solely fo...
Summary: Background: Global rollout of dolutegravir-based antiretroviral therapy (ART) has been ham...
Introduction: Evidence on health-related quality of life (HRQoL) outcomes is limited for new antiret...
Background: ART initiation in the 3rd trimester of pregnancy is associated with failure to achieve v...
BACKGROUND: Late initiation of HIV antiretroviral therapy (ART) in pregnancy is associated with not ...
BackgroundLate initiation of antiretrovirals in pregnancy is associated with increased risk of perin...
Background Late initiation of HIV antiretroviral therapy (ART) in pregnancy is associated with not a...
BackgroundThe global transition to use of dolutegravir (DTG) in WHO-preferred regimens for HIV treat...
Late initiation of antiretrovirals in pregnancy is associated with increased risk of perinatal trans...
Background: Effective antiretroviral therapy during pregnancy minimizes the risk of vertical HIV tra...
BackgroundRapid reduction in human immunodeficiency virus (HIV) load is paramount to prevent peripar...
Background: Pregnancy and polymorphisms in drug disposition genes alter the clearance of key antiret...
Item does not contain fulltextInformation on the extent of drug exposure to mothers and infants duri...
This case highlights the current complexities of managing women in the early stages of pregnancy pre...
Information on the extent of drug exposure to mothers and infants during pregnancy and lactation nor...
Background Women with HIV and prior exposure to combination antiretroviral therapy (cART) solely fo...
Summary: Background: Global rollout of dolutegravir-based antiretroviral therapy (ART) has been ham...
Introduction: Evidence on health-related quality of life (HRQoL) outcomes is limited for new antiret...
DOI
Add to ORKG